Plasma Succinylacetone (Succinylacetone)
Pathognomonic toxic metabolite formed from the spontaneous decarboxylation of accumulated fumarylacetoacetate in Tyrosinemia Type 1.
Standard vs. Optimal Reference Rangesumol/L
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<0.10 umol/L (undetectable)
General reference distribution across unselected commercial populations.
Undetectable (<0.05 umol/L)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Inhibits delta-aminolevulinic acid dehydratase (ALAD), causing porphyria-like neurological crises, acute liver failure, and early hepatocellular carcinoma.
Differential Diagnosis
Elevated Levels (Succinylacetone High)
- •Hereditary Tyrosinemia Type 1 (FAH gene mutation, severe hepatorenal disease)
- •Untreated metabolic crisis
Low Levels (Succinylacetone Low)
- •Nitisinone (NTBC) therapeutic success
- •Normal tyrosine degradation pathway
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Succinylacetone
- Targeted organ system imaging or functional dynamic testing related to fumarylacetoacetate hydrolase / tyrosinemia
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Plasma Succinylacetone - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Succinylacetone Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Plasma Succinylacetone (Succinylacetone) into overall healthspan optimization.